Biovica International AB (publ) (BIOVIC_B) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

and welcome to the BioVica webcast for the second quarter of our fiscal year 24-25. Today, it's going to be me, Anders Rylander, presenting together with my colleagues Hector Tamburini, Head of US Operations, and Henrik Winter, our SVP Business Development. And I will cover for Anders Morén, who is not participating to date. The agenda is first a short introduction to By Weekend or Productivitum. We'll go through the highlights during the second quarter. I'll do the financial update before handing over to Hector, who will do the update for US, and Henrik will do the update for Pharma Services. And lastly, I'll do a summaries and we will open up for a Q&A session. the Q&A session will be performed as we usually do it. We will let our equity analysts into the call to ask questions, and then after these questions are asked, we'll take questions from the chat so you have the ability to use the function Ask the Moderator. and you can submit it and I will ask, we will answer as many as we can. We will limit the call to an hour. And if we're not able to answer all the questions, we will ask them in writing and put them as an appendix to this presentation that will be put on our webpage. So if we go over to a very short introduction of what BioVica is and Divitum does, This is a schematic illustration of how the product works. The product divitum measures an enzyme which correlates to cell proliferation. And cell proliferation is something very essential when it comes to cancer, of course. That's how cancer grows. And with DIVITUM, we've shown that we can provide very important information both during and both before and during the treatment. Before the treatment, we can give an indication of how aggressive the disease is and also during treatment to provide feedback if the ...